On April 3, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported the latest data from its ongoing study on prostate cancer detection, utilizing Cchek, its artificial intelligence (AI) driven cancer detection technology, at the 2019 annual meeting of the American Association of Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Anixa Biosciences, APR 3, 2019, View Source [SID1234534984]). The meeting was held March 29–April 3, 2019 and was attended by world leading experts across the field of cancer research. Anixa’s presentation is available on the Company’s website, at: www.anixa.com/cchek/recent-data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Amit Kumar, CEO of Anixa, stated, "We are pleased with the response received on our presentation from the scientific community, and look forward to the impact our technology may have on cancer treatment."